Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Massachusetts General Hospital
60 participants
Dec 2, 2021
INTERVENTIONAL
Conditions
Summary
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited. Preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis, inflammation and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD. Post-menopausal women are a growing population with particularly high risk of NASH due to their lack of estrogen. This study will examine the effect of estradiol on hepatic fibrosis and fat in post-menopausal women with NASH.
Eligibility
Inclusion Criteria4
- Postmenopausal women 45-70 years old
- NASH by biopsy or NAFLD by imaging within 6 months of screen
- Hepatitis C antibody and hepatitis B surface antigen negative
- Negative mammogram within 1 year
Exclusion Criteria13
- Heavy alcohol use
- Use of NASH pharmacotherapies within 12 months of study entry
- Known cirrhosis, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam
- Participation in NASH clinical trial within 6 months of study entry
- Chronic use of corticosteroids, methotrexate, amiodarone, or tamoxifen within 6 months of entry
- Known diagnosis of chronic liver disease other than NAFLD or found on biopsy
- Contraindication to liver biopsy including INR \> 1.5, platelets \< 50,000/mL, ascites, chronic anticoagulation (other than aspirin), biliary obstruction, peritonitis, inability to lie supine for 30 minutes
- Hgb \< 10.0 g/dL or glomerular filtration rate \< 60 mL/min
- Contraindications to estrogen therapy
- Any vaginal bleeding, including spotting, within the last year
- Active malignancy
- Severe chronic illness
- Use of estrogen or progesterone within a year of baseline visit
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The patch will provide 100mcg of estradiol daily.
Placebo patch will contain no estradiol.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04833140